Lipid Disorders
News
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
Key clinical point: No increase in the risk of hospitalization for heart failure was found in a large cohort study that used an FDA surveillance...
Conference Coverage
ACCELERATE: Evacetrapib’s clinical failure sinks lipid-drug class
Key clinical point: Despite producing dramatically beneficially changes in lipid levels, treatment with evacetrapib failed to produce clinical...
Conference Coverage
STAMPEDE: Metabolic surgery bests medical therapy long term
CHICAGO – The superiority of metabolic surgery over intensive medical therapy for achieving glycemic control in patients with type 2 diabetes, as...
News
New analysis bolsters metformin as first line in type 2 diabetes
Key clinical point: Clinical trial data support the use of metformin monotherapy, as opposed to sulfonylurea monotherapy, as a first-line therapy...
News
Psoriasis tied to abdominal aortic aneurysm in nationwide study
Key clinical point: Psoriasis predicted abdominal aortic aneurysm in a large, population-based study. Major finding: The adjusted risk of...
Conference Coverage
PPI cuts GI events from low- and high-dose aspirin
Key clinical point: In patients at high risk of cardiovascular disease on dual-antiplatelet therapy, concurrent proton pump inhibitor treatment...
Conference Coverage
Ticagrelor cuts post-MI events in diabetes patients
Key clinical point: Among post-MI patients with diabetes, dual-antiplatelet therapy with aspirin and ticagrelor produced a significant drop in the...
Video
VIDEO: HOPE-3 bolsters primary prevention in intermediate-risk patients
News
USPSTF updates guideline for preventive aspirin therapy
Key clinical point: The USPSTF recommends that many adults aged 50-59 years start low-dose aspirin for primary prevention of cardiovascular...
News
FDA adds safety warnings to certain type 2 diabetes medications
Type 2 diabetes medicines that contain saxagliptin and alogliptin may increase the risk of heart failure, especially in patients who already have...
Conference Coverage
PCSK9 inhibitor overcomes muscle-related statin intolerance
CHICAGO – Muscle-related statin intolerance was reproducible in many patients, but most could tolerate and respond robustly to a PCSK9 inhibitor...